Uncategorized
Novaliq’s dry eye treatment yields positive topline results
A preservative free cyclosporine A solution consistently reduced corneal fluorescein staining in a phase 2 clinical trial evaluating the treatment for moderate to severe dry eye disease, according to a press release from the manufacturer Novaliq GmbH.The randomized, double-masked, vehicle-controlled, multicenter U.S. study enrolled 207 patients assigned to one of four groups: a 0.05% CyclASol group, a 0.1% CyclASol group, an open label active control group and a placebo group. Treatment lasted 4 months.